Basic Info
  • Grade: Pharmaceutical Grade

    Factory Location: Anqing Anhui province

    Main Sales Markets: North America,Central/South America,Eastern Europe,Australasia,Middle East,Africa

  • Monthly Production Capacity: 100kgs per year

    Packaging Information: 25kgs per drum

  • Delivery Lead Time: Deliver in two weeks from PO date

    Sample Provided: yes

    Payment Terms: T/T

    Selexipag (NS-304) is an orally available and long-acting IP receptor agonist prodrug, and its active form, MRE-269, is highly selective for the IP receptor. Selexipag (NS-304) inhibits the binding of [3H]Iloprost to the human and rat IP receptors in a concentration-dependent manner. The Ki is 260 nM for the human IP receptor and 2100 nM for the rat IP receptor. The intracellular cAMP levels in hIP-CHO cells are increased in a concentration-dependent manner by treatment with Selexipag (NS-304) with EC50 of 177nM. Selexipag (NS-304) also inhibits platelet aggregation in humans and monkeys with IC50 values of 5.5 and 3.4 μM, respectively, but it shows no inhibition in dogs

Send your message to this supplier
  • From:
  • To:
    Alicorn Pharmaceutical Co., Ltd
  • Send a Copy to this Email
  • Message:
    Upload Images / Files
    - Supports jpg, jpeg, png,
     gif, pdf, doc, docx,
     xls, xlsx, txt, rar and zip
    - Max upload 3 files;
     Max  total size: 3MB
    (0/3)

    Enter between 20 to 4,000 characters.This is not what you are looking for ? Post a Sourcing Request Now

  • Verification:
PharmaSources Customer Service